Consensus Celcuity Inc.

Stocks

CELC

US15102K1007

Biotechnology & Medical Research

Market Closed - Nasdaq 16:00:00 2026-08-28 EDT			5-day change	1st Jan Change
88.44 ^USD	-5.15%		-5.44%	-11.33%

08-26	Celcuity Inc Submits Supplemental New Drug Application to Fda for Revtorpyk (Gedatolisib) for Hr+/Her2-, Pik3ca Mutant Locally Advanced or Metastatic Breast Cancer	CI
08-26	Celcuity Submits Supplemental NDA for REVTORPYK in PIK3CA-Mutant Breast Cancer	MT

Evolution of the Average Target: Celcuity Inc.

Evolution of the Target Price: Celcuity Inc.

Changes in Analyst Recommendations: Celcuity Inc.

2ef974.JZ3jJSOwUGQ8wN_R_JSOsvsINZFfETwXpTXDNz5DNNI.CMSpTWH-BDNvte2eheT5_Ll8Z-loSW9A4m-IGmQzYoAI-qlhV8MnM2T45w~6cce42dbb46251ce56c687e9b68dc44a

Analysts' recommendations: Celcuity Inc.

05-04	U.S. research roundup - Alphabet, Colgate-Palmolive, Welltower	RE
05-04	HC Wainwright Upgrades Celcuity to Buy From Neutral, Adjusts Price Target to $165 From $94	MT
12-12	Wells Fargo Initiates Celcuity With Overweight Rating, $126 Price Target	MT
11-17	Celcuity Shares Fall After HC Wainwright Downgrade	MT
11-17	HC Wainwright Downgrades Celcuity to Neutral From Buy, Adjusts PT to $94 From $77	MT
11-17	HC Wainwright Downgrades Celcuity to Neutral From Buy, Price Target is $94	MT
11-12	Cancer diagnostics firm Celcuity posts smaller-than-expected Q3 adjusted loss per share	RE
25-10-18	Celcuity Provides Update on Status of the Pik3ca Mutated Cohort of Phase 3 Viktoria-1 Trial and Releases Additional Data Analysis from Phase 1B Clinical Trial	CI
25-09-22	Guggenheim Initiates Celcuity at Buy With $110 Price Target	MT
24-08-26	LifeSci Capital Initiates Coverage on Celcuity With Outperform Rating, $27 Price Target	MT
24-07-22	Leerink Partners Starts Celcuity With Outperform Rating, $29 Price Target	MT
24-05-31	Needham Trims Price Target on Celcuity to $23 From $24, Maintains Buy Rating	MT
24-05-16	Craig-Hallum Adjusts Price Target on Celcuity to $27 From $25, Assumes Buy Rating	MT
24-03-28	Craig Hallum Adjusts Celcuity Price Target to $25 From $20, Maintains Buy Rating	MT
24-03-28	Needham Adjusts Price Target on Celcuity to $24 From $23, Keeps Buy Rating	MT
24-02-22	Stifel Initiates Celcuity With Buy Rating, Price Target is $40	MT
23-12-08	HC Wainwright Starts Coverage on Celcuity with Buy Rating, $27 Price Target	MT
22-05-17	Craig Hallum Adjusts Celcuity Price Target to $20 From $30, Maintains Buy Rating	MT
22-05-17	Needham Adjusts Celcuity's Price Target to $25 from $50, Keeps Buy Rating	MT
21-10-08	Celcuity : Canaccord Genuity Starts Celcuity at Buy With $50 Price Target	MT
21-09-07	Celcuity : Jefferies Starts Celcuity at Buy with $48 Price Target	MT
21-07-29	Celcuity : Cowen Initiates Coverage on Celcuity With Outperform Rating	MT
21-07-27	Celcuity : Needham Starts Celcuity at Buy With $50 Price Target	MT
21-04-12	Celcuity : HC Wainwright Adjusts Celcuity's Price Target to $30 From $19, Maintains Buy Rating	MT
21-02-17	Celcuity : Craig-Hallum Adjusts Celcuity's Price Target to $24 From $19, Reiterates Buy Rating	MT

More recommendations

Bio Therapeutic Drugs

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	CELCUITY INC.					+82.15%
	WUXI APPTEC CO., LTD.					+16.85%
	ARGENX SE					+9.86%
	BIONTECH SE					+17.86%
	INSMED INCORPORATED					+68.87%
	WUXI BIOLOGICS (CAYMAN) INC.					+10.81%
	PHARMAESSENTIA CORPORATION					-13.15%
	GENMAB A/S					+12.58%
	SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.					+20.2%
	EXELIXIS, INC.					-2.66%
	Average					+22.34%
	Weighted average by Cap.					+17.33%